Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

OncoResponse

OncoResponse
2015 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
Series B LATEST DEAL TYPE
$6.7M LATEST DEAL AMOUNT
16 INVESTORS
Description

Developer of therapeutic antibodies designed to provide care against immuno-oncology targets. The company's technology uses a proprietary B-cell technology platform to mine the immune system of cancer patients who have responded to cancer immunotherapy to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies to treat cancer. The company has several antibodies directed at modulating immunosuppression of the tumor microenvironment in pre-clinical development.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 1124 Columbia Street
  • Suite 300
  • Seattle, WA 98104
  • United States

+1 (206) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore OncoResponse’s full profile, request a free trial.

OncoResponse Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series B) 14-Jun-2019 $6.7M 000.00 000.00 Completed Pre-Clinical Trials
3. Early Stage VC (Series B) 01-Sep-2018 0000 000.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series A) 23-Mar-2017 $29.5M $29.5M 000.00 Completed Generating Revenue
1. Joint Venture 06-Oct-2015 Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

OncoResponse Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00.00 00 00 00 00 00.000
To view this company’s complete Cap Table, request access »

OncoResponse Competitors (25)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
UNUM Therapeutics Formerly VC-backed Cambridge, MA 00 00000 000000 - 000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
0000000 00000000 Formerly VC-backed Cambridge, MA 00 00000 000000 - 000 00000
0000 000000000000 Formerly VC-backed Cambridge, MA 00 00000 000000&0 00000
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
To view this company’s complete list of competitors, request access »

OncoResponse Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 000000000 07-Nov-2017 000000000000000000 Biotechnology 00000000 000000
To view this company’s complete investment and acquisition history, request access »

OncoResponse Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Qatar Investment Authority Sovereign Wealth Fund Minority 000 0000 000000 0
Redmile Group Hedge Fund Minority 000 0000 000000 0
Alexandria Real Estate Equities Real Estate Minority 000 0000 000000 0
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
ARCH Venture Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »

OncoResponse Executive Team (5)

Name Title Board
Seat
Contact
Info
Clifford Stocks Co-Founder, Chief Executive Officer & Board Member
Kamal Puri Chief Scientific Officer

3 Former Executives

You’re viewing 2 of 5 executives. Get the full list »

OncoResponse Board Members (8)

Name Representing Role Since Contact
Info
Andrew Perlman GreatPoint Ventures Board Member 000 0000
Clifford Stocks OncoResponse Co-Founder, Chief Executive Officer & Board Member 000 0000
John McKearn Ph.D RiverVest Venture Partners Board Member 000 0000
Nathan Jorgensen Self Board Member 000 0000
Roberto DePonti Helsinn Healthcare Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 8 board members. Get the full list »